Impact of pre-hospital antibiotic therapy on mortality in invasive meningococcal disease: a propensity score study.


Journal

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 12 03 2019
accepted: 17 05 2019
pubmed: 30 5 2019
medline: 20 12 2019
entrez: 30 5 2019
Statut: ppublish

Résumé

The role of pre-hospital antibiotic therapy in invasive meningococcal diseases remains unclear with contradictory data. The aim was to determine this role in the outcome of invasive meningococcal disease. Observational cohort study of patients with/without pre-hospital antibiotic therapy in invasive meningococcal disease attended at the Hospital Universitari de Bellvitge (Barcelona) during the period 1977-2013. Univariate and multivariate analyses of mortality, corrected by propensity score used as a covariate to adjust for potential confounding, were performed. Patients with pre-hospital antibiotic therapy were also analyzed according to whether they had received oral (group A) or parenteral antibiotics (early therapy) (group B). Five hundred twenty-seven cases of invasive meningococcal disease were recorded and 125 (24%) of them received pre-hospital antibiotic therapy. Shock and age were the risk factors independently related to mortality. Mortality differed between patients with/without pre-hospital antibiotic therapy (0.8% vs. 8%, p = 0.003). Pre-hospital antibiotic therapy seemed to be a protective factor in the multivariate analysis of mortality (p = 0.038; OR, 0.188; 95% CI, 0.013-0.882). However, it was no longer protective when the propensity score was included in the analysis (p = 0.103; OR, 0.173; 95% CI, 0.021-1.423). Analysis of the oral and parenteral pre-hospital antibiotic groups revealed that there were no deaths in early therapy group. Patients able to receive oral antibiotics had less severe symptoms than those who did not receive pre-hospital antibiotics. Age and shock were the factors independently related to mortality. Early parenteral therapy was not associated with death. Oral antibiotic therapy in patients able to take it was associated with a beneficial effect in the prognosis of invasive meningococcal disease.

Identifiants

pubmed: 31140070
doi: 10.1007/s10096-019-03599-8
pii: 10.1007/s10096-019-03599-8
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1671-1676

Références

Arch Intern Med. 1999 Oct 25;159(19):2329-40
pubmed: 10547173
J Infect. 2002 Oct;45(3):144-51
pubmed: 12387769
N Z Med J. 2003 Sep 26;116(1182):U603
pubmed: 14581955
BMJ. 1992 Jul 18;305(6846):143-7
pubmed: 1515827
Scand J Infect Dis. 2004;36(4):274-9
pubmed: 15198184
BMJ. 2006 Jun 3;332(7553):1295-8
pubmed: 16554335
BMJ. 2006 Jun 3;332(7553):1299-303
pubmed: 16740557
J Infect. 2007 Jun;54(6):551-7
pubmed: 17147958
Lancet. 2007 Jun 30;369(9580):2196-2210
pubmed: 17604802
BMC Public Health. 2009 Apr 03;9:95
pubmed: 19344518
Curr Opin Pediatr. 2009 Aug;21(4):437-43
pubmed: 19421058
J Infect. 2013 Feb;66(2):147-54
pubmed: 23168216
Cochrane Database Syst Rev. 2013 Aug 02;(8):CD005437
pubmed: 23908052
Curr Neurol Neurosci Rep. 2015 Mar;15(3):2
pubmed: 25637287
J Infect. 2016 Jun;72(6):768-769
pubmed: 27085199
J Infect. 2017 Nov;75(5):420-425
pubmed: 28847701
Arch Intern Med. 1986 Dec;146(12):2380-2
pubmed: 3778073
Commun Dis Rep CDR Rev. 1995 Dec 8;5(13):R189-95
pubmed: 8556102
J Med Microbiol. 1996 Jul;45(1):16-20
pubmed: 8667405
Public Health. 1996 Jul;110(4):237-9
pubmed: 8757705
JAMA. 1997 Aug 13;278(6):491-6
pubmed: 9256224
J Accid Emerg Med. 1998 Mar;15(2):72-6
pubmed: 9570044
J Clin Epidemiol. 1998 Sep;51(9):717-21
pubmed: 9731919

Auteurs

Carmen Cabellos (C)

Infectious Diseases Service, IDIBELL-Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain. ccabellos@bellvitgehospital.cat.

Ivan Pelegrín (I)

Infectious Diseases Service, IDIBELL-Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.

Eva Benavent (E)

Infectious Diseases Service, IDIBELL-Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.

Francesc Gudiol (F)

Infectious Diseases Service, IDIBELL-Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.

Fe Tubau (F)

Microbiology Service, IDIBELL-Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.

Dolores Garcia-Somoza (D)

Microbiology Service, IDIBELL-Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.

Ricard Verdaguer (R)

Microbiology Service, IDIBELL-Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.

Javier Ariza (J)

Infectious Diseases Service, IDIBELL-Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.

Pedro Fernandez Viladrich (PF)

Infectious Diseases Service, IDIBELL-Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH